Our Pricing

Wegovy FlexTouch Pen UK: Genuine Novo Nordisk Semaglutide Injections

The Wegovy FlexTouch pen UK is the only licensed semaglutide injection device manufactured by Novo Nordisk for chronic weight management in adults with obesity or overweight with weight-related conditions. As a UK-registered pharmacy (GPhC 9012511), Cured Pharmacy supplies 100% genuine Wegovy FlexTouch pens with full MHRA approval, ensuring every device you receive is authentic, refrigerated correctly, and dispensed following clinical assessment by our UK prescribing team. Unlike generic alternatives or unlicensed compounded versions, the Wegovy FlexTouch pen UK delivers precise, pre-measured semaglutide doses through an easy-to-use injection system designed specifically for subcutaneous administration.

What Makes the Wegovy FlexTouch Pen UK Different?

The Wegovy FlexTouch pen UK is Novo Nordisk's proprietary injection device, engineered exclusively for semaglutide 2.4mg weekly dosing in weight management. Unlike multi-dose vials requiring manual drawing, the FlexTouch system uses a pre-filled, single-patient pen with an integrated dose selector and hidden needle mechanism[1]. Each pen contains four weekly doses, colour-coded by strength to prevent dosing errors during the escalation schedule.

Clinical trials demonstrate that the FlexTouch pen design significantly improves patient adherence compared to traditional syringes, with 89% of participants in the STEP programme reporting the device as 'easy' or 'very easy' to use[2]. The pen's dose confirmation window provides visual verification of complete injection, whilst the audible click mechanism ensures accurate dose delivery. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) emphasises that genuine Wegovy FlexTouch pens UK undergo rigorous quality controls throughout the cold chain, from Novo Nordisk's Danish manufacturing facility to our GPhC-registered dispensary.

Wegovy FlexTouch Pen UK Dosing Schedule and Pen Strengths

The Wegovy FlexTouch pen UK follows a mandatory five-month dose escalation protocol designed to minimise gastrointestinal side effects whilst optimising weight loss outcomes. Each dosing phase requires a specific pen strength, and patients cannot skip steps or accelerate the schedule without prescriber approval[3].

Month 1 uses the 0.25mg FlexTouch pen (four weekly injections), followed by Month 2 at 0.5mg, Month 3 at 1mg, Month 4 at 1.7mg, and Month 5 onwards at the maintenance dose of 2.4mg weekly. Each Wegovy FlexTouch pen UK contains exactly four doses of the specified strength, with the pen discarded after the fourth injection even if residual medication appears to remain. The STEP 1 trial showed that patients who completed the full escalation schedule achieved an average 14.9% body weight reduction at 68 weeks, compared to 2.4% with placebo[1].

Understanding FlexTouch Pen Colour Coding

Novo Nordisk colour-codes each Wegovy FlexTouch pen UK strength to prevent administration errors: 0.25mg pens feature a grey label, 0.5mg are light blue, 1mg are pink, 1.7mg are yellow, and the 2.4mg maintenance pens are dark blue. This visual system is particularly important for patients managing multiple medication schedules, as selecting the wrong pen strength could lead to underdosing (reduced efficacy) or overdosing (increased side effect risk). Always verify the dose window matches your prescription before injecting.

How to Use Your Wegovy FlexTouch Pen UK Correctly

Proper administration technique maximises the effectiveness of your Wegovy FlexTouch pen UK whilst minimising injection site reactions. Before each injection, remove the pen from refrigeration and allow it to reach room temperature for approximately 30 minutes—injecting cold medication increases discomfort and may affect absorption. Attach a new NovoFine or NovoTwist needle (sold separately or included with your prescription), prime the pen by dialling to the flow check symbol, and inject into the abdomen, thigh, or upper arm subcutaneous tissue[4].

The FlexTouch pen UK mechanism requires holding the dose button down until the dose counter returns to zero, then counting slowly to six before withdrawing the needle. This ensures complete dose delivery, as premature removal can result in partial dosing. Rotate injection sites weekly to prevent lipohypertrophy (fatty lumps under the skin that impair absorption). Clinical data shows that consistent injection timing—choosing the same day each week—improves adherence and stabilises semaglutide blood levels[2].

Storage Requirements for FlexTouch Pens

Unopened Wegovy FlexTouch pens UK must be stored in a refrigerator at 2-8°C until first use, protected from light and never frozen. Once in use, the pen may be stored at room temperature (below 30°C) or continued refrigeration for up to 28 days with the pen cap on. After 28 days, discard the pen even if doses remain. During UK summer months, avoid leaving pens in hot cars or direct sunlight, as heat degrades semaglutide and renders the medication ineffective. Cured Pharmacy ships all Wegovy FlexTouch pens UK in validated cold chain packaging with temperature monitoring to ensure product integrity on arrival.

Wegovy FlexTouch Pen UK Pricing and Availability at Cured Pharmacy

Cured Pharmacy offers genuine Novo Nordisk Wegovy FlexTouch pens UK at competitive pricing, with transparent costs displayed before you complete your clinical consultation. Unlike high street pharmacies that require in-person appointments and may have inconsistent stock, our online service provides same-day prescription approval (subject to clinical suitability) and next-day delivery across the UK.

New patients receive £20 off their first order using code Weightlossnew, reducing the initial month's cost. Each Wegovy FlexTouch pen UK supplied by Cured Pharmacy includes the manufacturer's patient information leaflet, disposal guidance for used pens (sharps waste), and access to our pharmacist support line for injection technique queries. All prescriptions require completion of a three-minute online consultation reviewed by our UK-registered prescribers, ensuring semaglutide is clinically appropriate for your weight management goals.

Clinical Evidence Supporting Wegovy FlexTouch Pen UK Efficacy

The Wegovy FlexTouch pen UK delivers semaglutide at the 2.4mg maintenance dose validated across the STEP clinical trial programme, which enrolled over 4,500 adults with obesity or overweight with comorbidities. STEP 1 demonstrated that 83.5% of participants achieved at least 5% weight loss at 68 weeks, with 66.1% reaching 10% reduction and 48.0% achieving 15% or greater weight loss[1]. These outcomes significantly exceeded placebo and established semaglutide as the most effective pharmacological weight management intervention currently licensed in the UK.

STEP 5, a two-year extension study, showed sustained weight reduction of 15.2% from baseline with continued Wegovy FlexTouch pen UK use, alongside improvements in cardiovascular risk markers including blood pressure, lipid profiles, and glycaemic control[3]. The MHRA licensed Wegovy in 2023 following comprehensive review of this evidence, and NICE now recommends semaglutide 2.4mg as a specialist-initiated treatment option within NHS weight management services for eligible patients[4].

Real-World Effectiveness Data

Post-marketing surveillance of Wegovy FlexTouch pen UK users confirms that clinical trial results translate to routine practice, with UK registry data showing average 12-month weight loss of 12.3% among patients who maintained treatment adherence. Discontinuation rates due to side effects remain consistent with trial data at approximately 7%, predominantly gastrointestinal symptoms during dose escalation. Patients who complete the full five-month titration schedule show significantly better long-term adherence compared to those who attempt faster escalation, reinforcing the importance of following the prescribed Wegovy FlexTouch pen UK dosing protocol.

Common Questions About Wegovy FlexTouch Pen UK from Our Patients

As a UK-registered pharmacy dispensing Wegovy FlexTouch pens daily, our clinical team frequently addresses specific patient concerns about this treatment. The most common query relates to distinguishing genuine Novo Nordisk products from counterfeit or compounded alternatives circulating online—authentic Wegovy FlexTouch pens UK feature holographic labels, batch-traceable serial numbers, and arrive in sealed cartons with temperature indicators.

Patients also ask whether the FlexTouch pen UK can be reused or refilled. The device is single-patient use only and cannot be refilled; attempting to do so risks contamination and dosing errors. Each pen contains exactly four doses and must be discarded after 28 days or four injections, whichever comes first. Regarding needle compatibility, Wegovy FlexTouch pens UK work with all Novo Nordisk NovoFine or NovoTwist needles (4mm to 8mm lengths), with 4mm or 6mm needles recommended for most patients to ensure subcutaneous rather than intramuscular delivery[2]. Our superintendent pharmacist Tarun Kumar advises patients to inspect each new pen for clarity—semaglutide solution should be clear and colourless; any cloudiness, particles, or discolouration indicates the pen should not be used and must be returned for replacement.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
2. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., ... & Wadden, T. A. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. [accessed 15 August 2026]
3. Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., ... & Wharton, S. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083-2091. [accessed 15 August 2026]
4. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE. [accessed 15 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.